ORIC Pharmaceuticals Reports 2024 Progress and Key Phase 1b Data

ORIC Pharmaceuticals, Inc., a clinical-stage oncology company, announced a notable performance in 2024, specific to early Phase 1b data for ORIC-944 and business operations. ORIC-944, a selective oral allosteric PRC2 inhibitor, showed significant efficacy in the treatment of mCRPC in terms of deep PSA reduction and favorable tolerability when combined with apalutamide or darolutamide. These outcomes support the profile of ORIC-944 as a first-line therapy, with dosing escalation continuing and phase 3 trials expected in the first quarter of 2026.

It also had progress with ORIC-114, which is an EGFR/HER2 inhibitor targeted at NSCLC, and moved to the clinical trials phase, Johnson & Johnson and Bayer collaborations. As per the CEO, Jacob M. Chacko, MD, the company achieved quite a significant feat in 2024 by setting the course for seven data readouts in the next 18 months towards addressing the vital challenge of therapeutic resistance in oncology. PIPE financing worth $125 million, coupled with the collaborations, is readying ORIC for 2025 and beyond.